Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NN 9277

Next Previous
Drug Profile

NN 9277

Alternative Names: GG-co-agonist 1177; NN9277; NNC 9204 1177

Latest Information Update: 11 Aug 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Obesity therapies
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 30 Jun 2020 Discontinued - Phase-I for Obesity in USA (SC) due to prioritisation within the obesity care development portfolio
  • 21 Jan 2020 NN 9277 is still in phase-I trials for Obesity (Novo Nordisk pipeline, January 2020)
  • 03 Jan 2020 Novo Nordisk completes a phase I trial in Obesity in USA (NCT03308721) (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top